A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis

Min Jeong Kim; Ji Hyun Lee; Ho Joon Im; Hyun Jung Yeo; Hong Jik Lee; Ki Sup Byun

doi:10.4078/jrd.2014.21.5.274

Journal List > J Rheum Dis > v.21(5) > 1064140

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Lee, Im, Yeo, Lee, and Byun: A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis

Case Report

J Rheum Dis 2014;21(5):274-277.

Published online: 31 October 2014

DOI: https://doi.org/10.4078/jrd.2014.21.5.274

A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis

Min Jeong Kim, Ji Hyun Lee, Ho Joon Im, Hyun Jung Yeo, Hong Jik Lee, Ki Sup Byun

Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, Korea

Corresponding to: Ji Hyun Lee, Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, 121, Junggu-ro, Jung-gu, Busan 600-730, Korea. E-mail: ete@lycos.co.kr

Received 16 September 2013 Revised 3 December 2013 Accepted 4 December 2013

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Infliximab, which is indicated for refractory rheumatoid arthritis (RA), ankylosing spondylitis (AS) and Crohn's disease, has cutaneous adverse events including skin rash, urticaria, pruritus, and lupus-like eruption. Psoriasis induced by infliximab is very rare. In Korea, it is infrequently reported in Crohn's disease or RA and never reported in AS. We encountered a case of psoriasis induced by infliximab treatment for AS, and report here on this case along with a review of the relevant literature.

Keywords: Infliximab, Psoriasis, Ankylosing spondylitis

REFERENCES

1. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005; 7:R666–76.

2. Famenini S, Wu JJ. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dermatol. 2013; 12:939–43.

3. Kim JY, Choi M, Cho KH. A case of pustular psoriasis developed during infliximab treatment for crohn's disease. Korean J Dermatol. 2012; 50:810–3.

4. Jwa YJ, Kim NH, Park HJ, Park JS, Bae WK, Kim KA, et al. A case of psoriasis induced by infliximab treatment for Crohn's disease. Korean J Gastroenterol. 2010; 56:324–8.

5. Park BC, Lim HJ, Kim BS, Lee WJ, Kim do W, Lee SJ. Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease. Ann Dermatol. 2009; 21:60–2.

6. Choi YJ, Kim DS, Park JM, Oh SH, Park YK, Lee JH. A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy. Korean J Dermatol. 2008; 46:721–3.

7. Kim SY, Kim GM, Kim SY. Case of recurrent generalized pustular psoriasis treated with a combination of infliximab with methotrexate and retinoid. Korean J Dermatol. 2006; 44:67–70.

8. Oh JM, Koh EM, Kim H, Lee J, Ahn JK, Cha HS, et al. Exacerbation of psoriatic skin lesion followed by tnfalpha antagonist treatment. J Korean Rheum Assoc. 2010; 17:200–4.

9. Park JJ, Lee SC. A Case of Tumor Necrosis Factor-alpha Inhibitors-induced Pustular Psoriasis. Ann Dermatol. 2010; 22:212–5.

10. Hahn HJ, Jung JW, Park HJ, Lee YW, Choe YB, Ahn KJ. A case of psoriasiform dermatitis following adalimumab injection for treatment of ankylosing spondylitis. Korean J Dermatol. 2013; 51:743–5.

11. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496–509.

12. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58:501–8.

13. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012; 30:700–6.

14. Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140:1490–5.

15. Aeberli D, Seitz M, Jüni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005; 44:172–5.

Figure 1.

(A) Erythematous scaly plaques on extensor surfaces of lower extremities (B) pustules with reddened skin of palm.

Figure 2.

Anteroposterior radiograph of the pelvis showing periarticular erosions and sclerosis of both sacroiliac joints.

Figure 3.

Microscopic finding of the skin lesion. Hyperkeratosis, dermal papillar elongation, perivascular lymphocytic infiltration were seen (H&E stain, ×100).

TOOLS

Similar articles